Health news
Funding round led by Valspring Capital, a new growth equity fund founded by the former Bain Capital Ventures healthcare investment team; brings total funding raised to date to more than $108M.
…
The referral program is the latest in the software company’s push to improve immunization and illness tracking in hospitals, educational institutions, and other organizations
CHICAGO – October 27, 2022 – (Newswire.com)
Immuware, a Chicago-based software company that provides innovative immunization and illness tracking systems, is excited to announce the launch of a new referral program for clients. The recently developed program will reward clients for referrals by providing referring organizations with a credit of $2,500 toward their next invoice for any referrals that sign a contract of three years or more.
The new referral program is intended to thank Immuware’s existing clients for recommending the company’s software products to other users. And because the program is ongoing, organizations can continue to refer Immuware as many times as they’d like, receiving a $2,500 credit each time a client signs on for a three-plus-year contract term.
Immuware’s quick-to-deploy software solutions are essential for organizations that require tracking illness and injuries among employees. Through key system features like real-time dashboards, automated end-to-end compliance workflows, HIPAA-secure cloud hosting, and a permission-based online employee portal, Immuware makes it easy to maintain accurate data on employee immunization, illness, and injury status, regardless of the size or scope of a workforce.
Clients enjoy flexible and scalable features for employee and occupational health monitoring, with comprehensive solutions that raise the bar for what organizations can expect out of their health tracking software. And through the referral program, Immuware hopes to help even more clients save time and money and reduce the errors that can come with manual reporting.
Immuware clients have been shown to reach compliance at least 40% faster than non-users, and have a dedicated partner in tracking all of the data that matters to the health of their workforce and facilities. This means that not only are organizations able to easily meet mandatory regulatory requirements, but they are also able to better protect the employees who are crucial to their day to day operations.
Current Immuware clients are encouraged to participate in the new referral program and take advantage of big savings on one or more future invoices. As previously mentioned, clients will be credited $2,500 for every organization they refer that signs on for a three or more year contract with Immuware, and can gain this credit every time they make an eligible referral.
To learn more, please visit the Immuware homepage for additional information on Immuware software features and benefits, or contact Immuware directly today.
About Immuware
Immuware is a software company and consulting firm that provides businesses in the healthcare, energy, education, and government sectors with secure and easy-to-use health tracking solutions. Immuware applications include innovative vaccination management and illness tracking software, plus streamlined compliance status dashboards that increase accountability and take the guesswork out of identifying compliance gaps.
Visit www.immuware.com for more information.
Contact:
Immuware
(312) 505-1443
[email protected]
Contact Information:
Alexandria Onwuteaka
Marketing & Sales Coordinator
3125051443
Press Release Service
by
Newswire.com
Original Source:
Immuware Launching New Referral Program Where Organizations Can Earn Credit
Soldiers in the Myanmar military have admitted to carrying out gross human rights abuses on the orders of the military. Six soliders – who recently defected – have given rare in-depth interviews to the BBC in which they describe killing and raping civilians and the burning of villages. The military seized power from the democratically-elected…
At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences’ proprietary PhAROS drug discovery platform.
LAS VEGAS – October 27, 2022 – (Newswire.com)
Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating their AI-enabled drug discovery engines’ ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California. In her session entitled “The Use of an AI-enabled Drug Discovery Engine to Identify Plant-Inspired Pharmaceuticals,” Dr. Small-Howard will introduce PhAROS™, Gb Sciences’ proprietary AI-enabled drug discovery platform. Dr. Small-Howard will also present case studies establishing how the company has utilized PhAROS™ to combine information from plant-based medical systems with modern in silico drug discovery tools that identify novel plant-inspired therapies for treating critical medical needs.
“Gb Sciences is combining knowledge from plant-based traditional medical systems with modern in silico drug discovery tools. We are leveraging our AI-enabled platform with its unique database of known traditional medical plant species to uncover novel minimum essential mixtures of ingredients with therapeutic benefits and reduced side effect profiles. Our AI-enabled drug discovery platform also reduces the time and money needed to get results,” said Dr. Andrea Small-Howard. “With current drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain or novel options for patients suffering with anxiety and depression, we are establishing the value in exploring plants associated with traditional medicines to discover new drug molecules and simplified mixtures.”
Dr. Andrea Small-Howard of Gb Sciences was recently featured on MarketScale’s “IDC with Kevin Stevenson” podcast in an episode entitled “Bringing Medicines to Market Faster Through Analytics and Machine Learning” where she discussed the need for digital transformation in the biopharma industry and the fact that Gb Sciences is ahead of the majority of the industry through the development and use of their PhAROS™ platform for drug discovery.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Contact Information:
Madeleine Moench
Press Release Service
by
Newswire.com
Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo’s Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.
PHILADELPHIA – October 27, 2022 – (Newswire.com)
This contract follows Senzo’s recent announcements about the receipt of ISO 13485:2016 certification, and completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C.
Senzo’s core innovation is its Amplified Lateral Flow (ALF) technology which significantly increases the sensitivity of traditional-format lateral flow tests while maintaining specificity. The end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test, the industry’s gold standard test. The ability to incorporate amplification into a lateral flow test has long been a goal for diagnostics test makers but one which has proven difficult to achieve due to the tendency for amplified tests to return false positives. Senzo recently announced results from a blinded, third-party R&D study demonstrating that its Amplified Lateral Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even in cases with very low viral levels, which could allow for substantially better and earlier detection of virus compared to current lateral flow tests.
“The faster we can accurately diagnose, the sooner we can take action, begin treatment, and the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers PCR accuracy at the point of care, without the need to send a sample to a laboratory, will improve healthcare— it’s that simple. BARDA’s support of our ALF technology will be instrumental in helping us advance our ultimate goal of bringing ALF tests to market,” said Jeremy Stackawitz, CEO of Senzo.
This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00041.
About Senzo:
Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies focussed on enhanced sensitivity, to create mobile, point-of-care, self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products to bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com.
Contact Information:
Alex Mohacs
Sales & Marketing
Press Release Service
by
Newswire.com
Original Source:
Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test
Jaden Smith Rages At Jada Smith For Sleeping With His Friend August Alsina found himself in the spotlight again because of his infamous entanglement with Jada Smith and fans can’t stop referencing his friendship with Jaden Smith! So, did Jaden finally open up about his friend hooking up with his mom? Okay, for those who […]
This is the first sailing of the MSC Seashore out of Miami in November 2021. I know many people are interested in seeing what the ship looks like and what it offers. So in this Video 3, I will show you the food offered in the main dining restaurant (Tribeca and Central Park) and the […]
The post MSC SEASHORE – FOOD TOUR! | Miami Cruise | Video 3 first appeared on Miami In News.
A small displacement motorcycle has countless benefits: affordable price, small fuel consumption and light weight that ensures the
The Association Continues to Elevate its Board Membership with the Addition of High-Level Industry Experts Catherine Remy of LANXESS and Bertrand Lemont of OnScent
…
SportGait and Carrick Institute
WILMINGTON, N.C. – October 26, 2022 – (Newswire.com)
…
